| 摘要: |
| 目的 评估基线血清己糖激酶1抗体滴度与缺血性视网膜静脉阻塞（RVO）患者抗血管内皮生长因子（VEGF）治疗后视力改善的相关性。方法 2017年6月至2020年2月，我们调查了53例（共53眼）缺血性RVO继发黄斑水肿（RVO-ME）患者[23例视网膜中央静脉阻塞（CRVO）和30例视网膜分支静脉阻塞（BRVO）]和30例老年性白内障患者（对照组），采集基线血清，测定己糖激酶1抗体滴度。RVO患者接受了玻璃体内注射抗VEGF药物治疗。每3个月复诊时获取光学相干断层扫描图像。结果 治疗前，RVO-ME患者基线血清己糖激酶1抗体滴度显著高于对照组（0.148±0.097 AU vs. 0.062±0.083 AU，P＜0.001），且CRVO组患者血清己糖激酶1抗体滴度略高于BRVO组患者（0.189±0.096 AU vs. 0.118±0.088 AU，P=0.007）。RVO-ME患者基线血清己糖激酶1抗体滴度与基线时logMAR BCVA、中断光感受器椭圆体（EZ）带横向长度和视网膜中央厚度有关（P＜0.05）。治疗12个月后，该自身抗体的滴度仅与BCVA改善以及中断EZ带横向长度缩短有关（P＜0.05）。多元线性回归分析表明，12个月时logMAR BCVA仅与基线BCVA相关（P＜0.001）；此外logMAR BCVA和基线血清己糖激酶1抗体滴度与12个月时BCVA的改善有关（P＜0.05）。结论 己糖激酶1抗体是一种新的血清生物标记物，可预测RVO-ME患者抗VEGF治疗后更好的视力改善程度。 |
| 关键词: 视网膜静脉阻塞 己糖激酶1抗体 抗VEGF药物 视力改善 |
| DOI： |
| 分类号:R774 |
| 基金项目:北京市科技委员会首都临床特色应用研究与成果推广(Z17110001017029) |
|
| Relationship between serum hexokinase-1 antibody and visual improvement after anti-VEGF treatment in patients with ischemic retinal vein occlusion |
|
Wang Xizhe
|
|
Department of Ophthalmology,Xuanwu Hospital of Capital Medical University
|
| Abstract: |
| Objective To evaluate whether the baseline serum hexokinase-1 antibody be related to the visual improvement of patients with ischemic retinal vein occlusion (RVO) after anti-vascular endothelial growth factor (VEGF) treatment. Methods From June 2017 to February 2020, 53 patients (53 eyes in total) with macular edema secondary to ischemic RVO (RVO-ME) [23 patients with central retinal vein occlusion (CRVO) and 30 patients with branch retinal vein occlusion (BRVO)] and 30 patients with senile cataract (control group) were investigated. Baseline serum was collected and hexokinase 1 antibody titers were measured. RVO patients received intravitreal injection of anti-VEGF drugs. Optical coherence tomography images were obtained at the time of follow-up visit every 3 months. Results Before treatment, the baseline serum hexokinase 1 antibody titer of RVO-ME patients was significantly higher than that of the control group (0.148 ± 0.097 AU vs. 0.062 ± 0.083 AU, P＜0.001), and the serum hexokinase 1 antibody titer of CRVO patients was slightly higher than that of BRVO patients (0.189 ± 0.096 AU vs. 0.118 ± 0.088 AU, P=0.007). The baseline serum hexokinase-1 antibody titer of RVO-ME patients was related to logMAR BCVA and the transverse length of interrupted ellipsoid zones of photoreceptors (EZ) line at baseline (P＜0.05). After 12 months of treatment, the titer of the autoantibody was only related to the improvement of BCVA and the shortening of the transverse length of the interrupted EZ band (P＜0.05). Multiple linear regression analysis showed that logMAR BCVA was only related to baseline BCVA at 12 months (P＜0.001). In addition, logMAR BCVA and baseline serum hexokinase 1 antibody titers were related to the improvement of BCVA at 12 months (P＜0.05). Conclusion Hexokinase-1 antibody is a new serum biomarker, which can predict the better visual improvement of of RVO-ME patients after anti-VEGF treatment. |
| Key words: retinal vein occlusion hexokinase 1 antibody anti-VEGR drugs visual improvement |
